These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23849978)

  • 1. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
    Walenga JM; Lyman GH
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
    Cohen AT; Nandini B; Wills JO; Ota S
    Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
    O'Connell CL; Liebman HA
    Expert Rev Hematol; 2008 Dec; 1(2):175-82. PubMed ID: 21082922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboprophylaxis in non-surgical cancer patients.
    Cohen AT; Gurwith MM; Dobromirski M
    Thromb Res; 2012 Apr; 129 Suppl 1():S137-45. PubMed ID: 22682125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review.
    Duhl AJ
    J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of venous thromboembolism in patients with cancer.
    Noble S; Jenkins DA
    Br J Hosp Med (Lond); 2009 Jul; 70(7):380-5. PubMed ID: 19584778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of venous thromboembolism in cancer patients.
    Kakkar AK; Williamson RC
    Semin Thromb Hemost; 1999; 25(2):239-43. PubMed ID: 10357091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
    Borsig L
    Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of deep vein thrombosis in cancer patients.
    Lee AY
    Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer.
    Tran QN
    Am J Hosp Palliat Care; 2010 Sep; 27(6):416-9. PubMed ID: 20197558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing postsurgical venous thromboembolism: pharmacological approaches.
    Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
    Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients.
    Khorana AA
    Oncologist; 2007 Nov; 12(11):1361-70. PubMed ID: 18055857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.